美诺华: 宁波美诺华药业股份有限公司关于可转换公司债券2025年跟踪评级结果的公告

Group 1 - The core viewpoint of the announcement is that the credit rating for Ningbo Meinuo Pharmaceutical Co., Ltd. and its convertible bonds remains unchanged at AA- with a stable outlook [1][2] - The previous credit rating was also AA- for both the company and the convertible bonds, indicating consistency in the company's financial standing [1][2] - The credit rating was conducted by Zhongzheng Pengyuan Credit Rating Co., Ltd., based on a comprehensive analysis of the company's operations and industry conditions [2] Group 2 - The tracking credit rating report was issued on June 25, 2025, confirming the ratings and outlook [2] - The previous rating was conducted on June 26, 2024, with the same results [1][2] - The report is available on the Shanghai Stock Exchange website for further details [2]